VERAXA Biotech AG (NASDAQ: VRXA) has announced the appointment of Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister. The company stated that it is in the final stages of discussions with a permanent CFO candidate, who is expected to support the company's next phase of expansion and operational growth. An update on the permanent appointment will be provided in due course.
Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA's public listing. The company emphasized his experience in corporate finance, life sciences, and technology-driven businesses, as well as his familiarity with VERAXA's operations and strategic development, as key qualifications for leading the finance function during this transition period.
This leadership change comes as VERAXA progresses its pipeline of antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company's platform is built on transformative technologies and quality-by-design principles, aiming to advance its ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a leading research institution.
The interim CFO appointment ensures financial stability while the company seeks a permanent leader to drive its growth strategy. Investors can find the latest updates on VRXA in the company's newsroom at http://nnw.fm/VRXA. The full press release is available at https://nnw.fm/BjjY6.
